A study for a 57 year old man who takes Sandostatin Lar - from FDA reports


1,557 males aged 57 (±5) who take the same drug are studied. This is a personalized study for a 57 year old male patient who has Metastatic Carcinoid Tumor. The study is created by eHealthMe based on reports from FDA.



On Apr, 15, 2018

1,557 males aged 57 (±5) who take Sandostatin Lar are studied.


Number of reports submitted per year:

Sandostatin Lar for a 57-year old man.

Information of the patient in this study:

  • Age: 57
  • Gender: male
  • Conditions: Metastatic Carcinoid Tumor
  • Drugs taken:
    • Sandostatin Lar (octreotide acetate)

eHealthMe real world results:

Comparison with this patient's adverse outcomes:

  • Skin Nodule(slightly elevated lesions on or in the skin): 0 (0% of males aged 57 (±5) who take the drug)

As an adverse outcome could be a symptom of a condition, additional studies are listed to help identify the cause: for example, regardless of which drug is taken, how many female HBP patients aged 50 (±5) have nausea

As an adverse outcome could be a side effect of a drug, additional studies are listed to help identify the cause: for example, how many female Aspirin users aged 50 (±5) have nausea

Most common side effects over time

< 1 month:
  • High blood pressure
  • Diarrhea
  • Fatigue (feeling of tiredness)
  • Malaise (a feeling of general discomfort or uneasiness)
  • Blood pressure systolic increased
  • Abdominal pain
  • Nausea (feeling of having an urge to vomit)
  • Death
  • Injection site pain
  • Nausea and vomiting
1 - 6 months:
  • Death
  • Diarrhea
  • Nausea (feeling of having an urge to vomit)
  • Fatigue (feeling of tiredness)
  • High blood pressure
  • Malaise (a feeling of general discomfort or uneasiness)
  • Abdominal pain
  • Blood pressure systolic increased
  • Weight decreased
  • Malignant neoplasm progression (cancer tumour came back)
6 - 12 months:
  • Death
  • Malaise (a feeling of general discomfort or uneasiness)
  • Weakness
  • Abdominal pain
  • Malignant neoplasm progression (cancer tumour came back)
  • Fatigue (feeling of tiredness)
  • Diarrhea
  • Heart rate increased
  • Breathing difficulty
  • Blood pressure systolic increased
1 - 2 years:
  • Death
  • Fatigue (feeling of tiredness)
  • Blood pressure systolic increased
  • Weight decreased
  • Weakness
  • Diarrhea
  • Nausea (feeling of having an urge to vomit)
  • Malaise (a feeling of general discomfort or uneasiness)
  • Skin blushing/flushing (a sudden reddening of the face, neck)
  • Pain
2 - 5 years:
  • Abdominal pain
  • Fatigue (feeling of tiredness)
  • Nausea (feeling of having an urge to vomit)
  • Weakness
  • Hypotension (abnormally low blood pressure)
  • Back pain
  • Dizziness
  • Headache (pain in head)
  • Pain
  • Malignant neoplasm progression (cancer tumour came back)
5 - 10 years:
  • Malaise (a feeling of general discomfort or uneasiness)
  • Malignant neoplasm progression (cancer tumour came back)
  • Weight decreased
  • Peripheral swelling
  • Diarrhea
  • Abasia (inability to walk)
  • Weakness
  • Pain
  • Panic reaction
  • Spinal pain (pain in spine)
10+ years:
  • Weakness
  • Drug ineffective
  • Headache (pain in head)
  • Abdominal pain
  • Gynaecomastia (enlargement of the gland tissue of the male breast)
  • Breast lump (localized swelling that feels different from the surrounding breast tissue)
  • Breast calcifications (deposits of calcium that can be seen on a mammogram of the breast)
  • Nasopharyngitis (inflammation of the nasopharynx)
  • Breast pain
  • Injection site pain
not specified:
  • Diarrhea
  • Nausea (feeling of having an urge to vomit)
  • High blood pressure
  • Fatigue (feeling of tiredness)
  • Abdominal pain
  • Pain
  • Death
  • Nausea and vomiting
  • Weight decreased
  • Weakness

Top conditions involved for these people *:

  • Carcinoid Tumor : 243 people, 15.61%
  • Neuroendocrine Tumor : 224 people, 14.39%
  • Pancreatic Neuroendocrine Tumor : 83 people, 5.33%
  • High Blood Pressure : 57 people, 3.66%
  • Neuroendocrine Carcinoma (cancer tumour that arise from cells of the endocrine (hormonal) and nervous systems): 56 people, 3.60%

Top co-used drugs for these people *:

  • Afinitor (108 people, 6.94%)
  • Prilosec (49 people, 3.15%)
  • Omeprazole (45 people, 2.89%)
  • Lasix (44 people, 2.83%)
  • Zofran (43 people, 2.76%)

* Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Want to find out more about the FDA reports used in the study? You can request them from FDA.

Related tests

We suggest these affordable tests for self monitoring. You can order them and receive results on eHealthMe. No doctor referral or insurance necessary.

Expand the study to include reports from both FDA and eHealthMe

Expand this study to include FDA and eHealthMe reports

What are the drugs?

What are the conditions?

What are the symtoms?

Could your drugs cause:

Could your conditions cause:



Related studies:

Related publications that referenced our studies

You may be interested in these posts

More posts for: Sandostatin lar, Metastatic carcinoid tumor, Skin nodule

NOTE: The study is based on active ingredients. Other drugs that have the same active ingredients are also considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.